6-8 $'s pre R/S. I am no fan of a R/S however getting off the OTC is something the company views as a must by the end of this year. I'm just communicating what I believe the company is thinking and also their current valuation barometer. All this is obviously subject to change as we move forward.
For example if Pro-140 goes all the way through FDA approval as a single agent the valuation will be much higher. The company does not see that happening meaning a buy out much earlier in the process.
There are many moving parts here but once again it's all about completing enrollment and letting the empirical data decide Pro-140's fate. It really is that simple. We are going to get there and yes there will be more dilution, we just don't know how much and what the cost will be at this point in time.
All this adds up to those that want in are already in. Those that are in a wait and see are doing just that...we are all waiting on the news.
News 
Market Data 
Discover 
AI
